Latest market price
9.83
+0.13+1.34%
OverviewShort InterestFilings
CRVSQT25Corvus Pharmaceuticals, Inc.·NASDAQ
9.83+1.34%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE+3.92%$23.87RARE+2.02%$16.63NUVB+2.18%$4.69TRAX+2.86%$46.34NTLA+1.72%$11.86ABSI+3.20%$10.00URGN+0.12%$34.40MAZE+6.19%$32.25
Snapshot
Index—P/E—EPS (ttm)-0.64Insider Own37.54%Shs Outstand84.12MPerf Week-6.74%
Market Cap815.97MForward P/E—EPS next Y-0.94Insider Trans0.09%Shs Float64.80MPerf Month-8.47%
Enterprise Value600.97MPEG—EPS next Q-0.19Short Float27.73%Perf Quarter-29.43%
Income-54.00MP/S—EPS this Y—Short Ratio18.40Perf Half Y-37.39%
Sales0.00P/B3.63EPS next Y—ROA-22.62%Short Interest17.97MPerf YTD27.66%
Book/sh2.67P/C3.80EPS next 5Y—ROE-36.15%52W High26.95 -63.53%Perf Year22.26%
Cash/sh2.56P/FCF—EPS past 3/5Y—ROIC-25.20%52W Low6.39 53.83%Perf 3Y777.68%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility4.95% 5.49%Perf 5Y120.40%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.58Perf 10Y-31.21%
Dividend Ex-Date—Quick Ratio16.16Sales Y/Y TTM—Profit Margin0.00%RSI (14)38.48Recom2.08
Dividend Gr. 3/5Y—Current Ratio16.16EPS Q/Q-90.00%SMA20-2.56%Beta1.59Target Price27.00
Payout0.00%Debt/Eq0.00Sales Q/Q—SMA50-16.42%Rel Volume0.77Prev Close9.70
Employees37LT Debt/Eq0.00EarningsNov 05SMA200-32.05%Avg Volume1.01MPrice9.83
IPO DateMar 23, 2016Option/ShortYes / YesEPS/Sales Surpr.-19.41% —Net Debt/EBITDA—Volume776,101Change1.34%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedMizuho SecuritiesOutperform$30 → $27
Apr-17-26InitiatedGoldman SachsBuy$40
Jan-29-26ReiteratedMizuho SecuritiesOutperform$20 → $30
Jan-22-26ReiteratedJefferiesBuy$13 → $42
Jan-21-26ReiteratedOppenheimerOutperform$7.00 → $32
Jan-20-26ReiteratedMizuho SecuritiesOutperform$13 → $20
Jan-20-26ReiteratedHC Wainwright & Co.Buy$27
Oct-29-25ReiteratedMizuho SecuritiesOutperform$11 → $13
Oct-13-25InitiatedBarclaysOverweight$16
May-20-25ReiteratedMizuhoOutperform$12 → $11
Latest News· Times ET
Oct-29-26
Oct-29-2608:00AM
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026globenewswire.com
Oct-12-26
Oct-12-2604:53AM
Corvus Pharma Q2 2026 Earnings Call TranscriptBenzinga
Oct-01-26
Oct-01-2606:01AM
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?defenseworld.net
Sep-30-26
Sep-30-2604:05PM
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativaglobenewswire.com
Sep-25-26
Sep-25-2610:09AM
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?Yahoo
Sep-03-26
Sep-03-2608:30AM
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conferenceglobenewswire.com
Aug-27-26
Aug-27-2608:29AM
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis TreatmentSeekingAlpha
07:30AM
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trialglobenewswire.com
Aug-12-26
Aug-12-2606:26AM
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair ValueSeekingAlpha
Aug-07-26
Aug-07-2604:44AM
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-06-26
Aug-06-2608:04PM
Corvus Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
05:31PM
Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending ContinuesChartMill
04:01PM
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Resultsglobenewswire.com
Jul-30-26
Jul-30-2604:01PM
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com
Jul-19-26
Jul-19-2604:01AM
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 5.1% – Should You Buy?defenseworld.net
Company

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit
0000—————
Selling, General and Administrative Excl. Other11987—————
Research and Development45341917—————
Other Operating Expense101-1—————
Operating Income-57-43-28-23—————
Interest Expense
2000—————
Unusual Expense
—————————
Non-Operating Income (Expense)528-35-4—————
Net Income Before Taxes-53-15-62-27—————
Income Taxes
1000—————
Consolidated Net Income-54-15-62-27—————
Net Income From Continuing Operations-54-15-62-27—————
Net Income-54-15-62-27—————
EPS (Recurring)-0.64-0.19-1.02-0.56—————
EPS (Basic, Before Extraordinaries)-0.64-0.19-1.02-0.56—————
EPS (Diluted)-0.64-0.53-1.02-0.56—————
EBITDA-51-15-62-27—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding92796148—————
Market Capitalization90460832684—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.54$22.00$15.46$8.93$2.39● Close Price0.00K62.56K125.12K187.68K250.24KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Moore David ScottDirectorJun 11 '26Buy11.5321,700250,23621,700Jun 15
MILLER RICHARD A MDPresident and CEOMay 18 '26Buy12.046,93283,4531,195,035May 20
Thompson Peter A.Director, 10% OwnerJan 28 '26Option Exercise5.33210,0001,119,374210,000Jan 30
ORBIMED ADVISORS LLCDirector, 10% OwnerJun 27 '25Option Exercise3.501,397,6844,891,8948,341,338Jul 01
ORBIMED ADVISORS LLCDirector, 10% OwnerJun 27 '25Sale4.161,176,3324,891,8947,165,006Jul 01
Thompson Peter A.Director, 10% OwnerJun 27 '25Option Exercise3.501,397,6844,891,8948,341,338Jul 01
Thompson Peter A.Director, 10% OwnerJun 27 '25Sale4.161,176,3324,891,8947,165,006Jul 01
Jones William BentonOfficerJun 04 '25Option Exercise3.5019,35767,750173,130Jun 06
MILLER RICHARD A MDPresident and CEOMay 07 '25Option Exercise3.50559,0731,956,7561,136,707May 09
Thompson Peter A.Director, 10% OwnerMay 06 '24Buy1.722,841,7694,892,0381,444,085May 08
ORBIMED ADVISORS LLCDirector, 10% OwnerMay 06 '24Buy1.722,841,7694,892,0381,444,085May 08
Jones William BentonOfficerMay 06 '24Buy2.6039,357102,374153,773May 07
MILLER RICHARD A MDPresident and CEOMay 06 '24Buy2.601,136,7072,956,756577,634May 07
Grais LindaDirectorMay 15 '23Buy2.4510,00024,50010,000May 16
Jones William BentonOfficerDec 20 '22Buy0.7920,00015,800133,773Dec 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.